Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16415664 | 0.97 | FFAR3 (0.39) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL9067554 | 0.89 | TSHR (0.48) | FFAR3TSHRNFKB1CYP2C19 | |
| Hydrochloric Acid SCHEMBL11196712 | 0.87 | TSHR (0.47) | FFAR3TSHRNFKB1CYP2C19 | |
| Ethylene SCHEMBL11463450 | 0.85 | TSHR (0.45) | FFAR3TSHRNFKB1CYP2C19 | |
| Propene SCHEMBL11410149 | 0.79 | TSHR (0.41) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL14369404 | 0.77 | ESR1 (0.41) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL22341334 | 0.74 | GAA (0.39) | — | |
| Lithium Ion SCHEMBL16415663 | 0.72 | FFAR3 (0.32) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL30145016 | 0.70 | TSHR (0.38) | FFAR3TSHRNFKB1CYP2C19 | |
| SCHEMBL6045009 | 0.70 | CYP3A4 (0.42) | TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663546-B2 | Metal amides of cyclic amines | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160152649-A1 | METAL AMIDES OF CYCLIC AMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-06-02 | — | — | US | disclosed |
| WO-2015013630-A1 | METAL AMIDES OF CYCLIC AMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-01-29 | — | — | WO | disclosed |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-06-26 | — | — | US | disclosed |
| US-7378438-B2 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2008-05-27 | — | — | US | disclosed |
| EP-1503754-B1 | BETA-AGONIST COMPOUNDS COMPRISING NITRIC OXIDE DONOR GROUPS AND REACTIVE OXYGEN SPECIES SCAVENGER GROUPS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS | YISSUM RES DEV CO (IL) | 2005-11-23 | — | — | EP | disclosed |
| US-20050228184-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-10-13 | — | — | US | disclosed |
| EP-1503754-A1 | BETA-AGONIST COMPOUNDS COMPRISING NITRIC OXIDE DONOR GROUPS AND REACTIVE OXYGEN SPECIES SCAVENGER GROUPS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS | Yissum Research Development Company, of The Hebrew University of Jerusalem (IL) | 2005-02-09 | — | — | EP | disclosed |
| WO-2003088961-A1 | BETA-AGONIST COMPOUNDS COMPRISING NITRIC OXIDE DONOR GROUPS AND REACTIVE OXYGEN SPECIES SCAVENGER GROUPS AND THEIR USE IN THE TREATMENT OF RESPIRATORY DISORDERS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152649-A1 | METAL AMIDES OF CYCLIC AMINES | SRM, SMS, NBAS | FFAR3 4462/4885TSHR 2429/4885NFKB1 4031/4885 |
| US-20080149097-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disordersB | ADRA2B, ADRA1B, ADRB1 | FFAR3 238/4885TSHR 1485/4885NFKB1 1021/4885 |
| US-20050228184-A1 | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders | ADRB1, ADRB2, ADRB3 | FFAR3 137/4885TSHR 1366/4885NFKB1 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.